Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 19, 2015 8:00 AM ET


Company Overview of ADC Therapeutics Sarl

Company Overview

ADC Therapeutics Sarl develops antibody drug conjugates (ADCs) and non-antibody drug conjugate products. The company is based in Lausanne, Switzerland. ADC Therapeutics Sarl operates as a subsidiary of Celtic Therapeutics Holdings L.P.



Key Executives for ADC Therapeutics Sarl

Chief Executive Officer and Director
Co-Founder, Managing General Partner and Chairman
Age: 66
Director of Finance
Senior Vice President of Research & Development
Chief Medical Officer and Head of Oncology Clinical Development
Compensation as of Fiscal Year 2014.

ADC Therapeutics Sarl Key Developments

ADC Therapeutics Submits its First IND for a Novel Antibody Drug Conjugate Against Lymphomas

ADC Therapeutics Sarl announced that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas. The Phase I clinical trial will commence at four leading oncology centres in the USA, and can expand into two centres in the United Kingdom. The initial up to 58 patient adaptive designed dose-escalation study, will evaluate the tolerability, safety, pharmacokinetics and antitumor activity of ADCT-301 in patients with relapsed or refractory Hodgkin's and Non-Hodgkin's lymphoma. Subject to study results, ADC Therapeutics intends to rapidly expand the numbers of patients in the trial and the participating clinical centres.

ADC Therapeutics Announces Board Appointment

ADC Therapeutics announced expansion of its team as the company's first ADCs enter clinical development. New team members include: Dr. Jay Feingold joins as Chief Medical Officer and Head of Oncology Clinical Development. Dr. Feingold has more than 25 years of industry, academic and medical experience and was most recently Vice President, US Medical Affairs and Chairman Global Medical Affairs Oversight Committee at Daiichi Sankyo. Prior to this, he served as Vice President of Clinical Development, Global Therapy Area Director, Oncology at Wyeth. Dr. Michael Mulkerrin joins as Head of CMC (Chemistry Manufacturing and Control). Dr. Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech. Dr. Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recently as Global Head Biologics Safety Assessment and Executive Director at Novartis and has had prior senior roles at AstraZeneca, Syngenta and Quintiles. Mr. Stéphane Henchoz joins as Director of Finance, bringing more than 20 years pharmaceutical industry finance experience, most recently working at Merck Serono.

ADC Therapeutics and MedImmune Announces Update on Joint Venture

ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune. This follows the October 2013 announcement in which MedImmune entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT's antibody-drug conjugate programs in preclinical development. ADCT-401 targets Prostate-Specific Membrane Antigen (PSMA) a cell-surface antigen specifically expressed by prostate cancer cells. ADCT-401 comprises an anti-PSMA monoclonal antibody coupled with a pyrrolobenzodiazepine (PBD) warhead using a proprietary linker licensed from London-based Spirogen, a wholly owned subsidiary of MedImmune. Initial clinical studies will focus on hormone-refractory prostate cancer and an IND filing is anticipated in 2015. The PSMA-specific J591 antibody in ADCT-401 was developed by Dr. Neil H. Bander, the Bernard & Josephine Chaus Professor of Urologic Oncology and Director of Urological Oncology Research at the Weill-Cornell Medical College, New York. Dr. Bander is also Chairman of ADCT's Scientific Advisory Board. PSMA is a cell-surface antigen expressed by virtually all prostate cancer cells, including metastases, and also in the blood vessels that feed many other tumor types, but is rarely expressed in normal cells. This will be ADCT's second ADC program into the clinic from its pipeline of eleven programs with an IND filing expected in the first of these programs by the end of the year 2014. The pre-clinical development of ADCT-401 is being managed by a team of scientists based in laboratories at the Queen Mary Bioenterprises Innovation Centre, London which, being co-located with Spirogen, enables close co-operation between the two groups.

Similar Private Companies By Industry

Company Name Region
Merck & Cie Schaffhausen Europe
Acino Holding AG Europe
Galderma S.A. Europe
Mepha Pharma AG Europe
Arena Pharmaceuticals GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADC Therapeutics Sarl, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at